Building honest dialogue with patient advocatesHow can the industry listen to patients in a way that puts the person behind the disease first? Share XBuilding honest dialogue with patient advocateshttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/building-honest-dialogue-with-patient-advocates/
Turning words into actions with patient engagementBoehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients Share XTurning words into actions with patient engagementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/turning-words-into-actions-with-patient-engagement-boehringer-ingelheim/
How the patient voice is becoming vital for drug approvalRebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed Share XHow the patient voice is becoming vital for drug approvalhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/patient-voice-drug-approvals-lipodystrophy/
“A long way to go” for digital health reimbursementA recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations Share X“A long way to go” for digital health reimbursementhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/a-long-way-to-go-for-digital-health-reimbursement/
Time for a NICE changeThe National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and Share XTime for a NICE changehttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/time-for-a-nice-change/
Rethinking access barriers to innovationMarket access issues don’t stop once a product has passed HTA – and this is especially true for Share XRethinking access barriers to innovationhttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/rethinking-access-barriers-to-innovation/
AI meets RWE: The future of drug assessment?Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts Share XAI meets RWE: The future of drug assessment?https://pharmaphorum.com/views-analysis-market-access/ai-meets-rwe-the-future-of-drug-assessment/
Listening to ultra-rare disease communitiesWhen it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global Share XListening to ultra-rare disease communitieshttps://deep-dive.pharmaphorum.com/magazine/market-access-2021/qa-ptc-therapeutics-alberto-vicent-on-listening-to-the-ultra-rare-disease-communities/
NICE rejects J&J’s prostate cancer drug Erleada in initial guidanceNICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone Share XNICE rejects J&J’s prostate cancer drug Erleada in initial guidancehttps://pharmaphorum.com/news/nice-rejects-jjs-prostate-cancer-drug-erleada-in-initial-guidance/
